ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.175,21
1,01%
S&P 500
5.159,02
0,61%
Dow Jones
38.745,70
0,18%
Euro vs US Dollar
1,07743
0,15%
Bitcoin
63.471,85
-0,82%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Nuvalent Inc (NUVL)

  7. Nuvalent Inc (NUVL) News

NUVL Nuvalent Inc

69,38
-0,97 (-1,38%)
Zuletzt aktualisiert: 18:59:29
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Nuvalent Inc NUVL NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
-0,97 -1,38% 69,38 18:59:29
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
69,99 68,79 70,69 70,35
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
08.4.202422:30PRNUSNuvalent Presents New Preclinical Data Supporting Profiles..
05.3.202422:52PRNUSNuvalent to Present New Preclinical Data on HER2-Selective..
27.2.202413:00EDGAR2Form S-8 - Securities to be offered to employees in employee..
27.2.202412:42EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27.2.202412:38EDGAR2Form 8-K - Current report
27.2.202412:30PRNUSNuvalent Highlights Pipeline Progress, Reiterates Key..
27.2.202412:15PRNUSNuvalent Receives U.S. FDA Breakthrough Therapy Designation..
12.2.202412:30PRNUSNuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical..
01.2.202412:30PRNUSNuvalent to Participate in the Guggenheim Healthcare Talks..
09.1.202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.1.202422:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.1.202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.1.202422:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.1.202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.1.202422:40EDGAR2Form 8-K - Current report
08.1.202412:30PRNUSNuvalent Announces "OnTarget 2026" Operating Plan and Key..
28.12.202323:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.12.202322:31EDGAR2Form 144 - Report of proposed sale of securities
21.12.202312:30PRNUSNuvalent to Present at the 42nd Annual J.P. Morgan..
20.12.202322:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202322:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202322:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202300:00EDGAR2Form 144 - Report of proposed sale of securities
18.12.202323:45EDGAR2Form 144 - Report of proposed sale of securities
18.12.202323:32EDGAR2Form 144 - Report of proposed sale of securities
18.12.202323:23EDGAR2Form 144 - Report of proposed sale of securities
30.11.202322:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.11.202312:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14.11.202312:45EDGAR2Form 8-K - Current report
14.11.202312:30PRNUSNuvalent Highlights Corporate and Pipeline Achievements and..
03.11.202321:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.11.202311:30PRNUSNuvalent to Participate in the BMO Virtual BioPharma..
26.10.202322:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25.10.202300:01EDGAR2Form 144 - Report of proposed sale of securities
17.10.202322:07EDGAR2Form 8-K - Current report
17.10.202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
17.10.202303:55PRNUSNuvalent Announces Pricing of Public Offering of Common..
16.10.202313:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16.10.202313:30PRNUSNuvalent Announces Public Offering of Common Stock
13.10.202312:40EDGAR2Form 8-K - Current report
13.10.202312:30PRNUSNuvalent Reports Preliminary Phase 1 Clinical Data from..
06.10.202322:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.10.202322:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.10.202322:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.10.202322:12EDGAR2Form 144 - Report of proposed sale of securities
04.10.202322:05EDGAR2Form 8-K - Current report
04.10.202318:21PRNUSPreliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial..
19.9.202322:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.9.202312:30PRNUSNuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2..
06.9.202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Kürzlich von Ihnen besucht

NASDAQ
NUVL
Nuvalent
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten